US extension should to some extent.
Revenues are in the US. So shoring up another 9 years give or take is a positive.
Axiron isn't even approved in Australia and is likely to be a small market.
But of course this is all forward looking. Whereas all the market currently cares about at the moment is the now.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $19.90K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 463664 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 320000 | 2 |
View Market Depth
| Last trade - 15.56pm 25/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |